MANNATECH INC Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs
MANNATECH INC (MTEX) had Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs of $218.00 thousand as of 2022-12-31, per its 10-K filed 2023-03-17.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities
us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts · last filed 2023-03-17
- 2022-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $218.00K.
- 2021-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $0.00.
| Period end | Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs |
|---|---|
| 2022-12-31 | $218.00K 10-K · filed 2023-03-17 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B | |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Cronos Group Inc. (CRON) | $1.223B | ||
| Definium Therapeutics, Inc. (DFTX) | United States | $4.931B | -17.87 |